



Bile microbiota in Pancreatic and Extra-Pancreatic Biliary Tract Cancer: A New STROBE retrospective cohort study

Autori: Paola Di Carlo^{1*}, Nicola Serra², Teresa Maria Fasciana¹, Francesco D'Arpa³, Erika Di Marco¹, Consolato M. Sergi⁴ and Antonio Cascio¹

Affiliazioni: 1. Department of Health Promotion, Maternal-Childhood, Internal Medicine of Excellence "G. D'Alessandro", University of Palermo, 90127, Italy 2. Department of Public Health, University Federico II of Naples, Italy. 3. Department of General Surgery and Emergency, University of Palermo, Italy. 4. Lab. Med. and Pathology, Children's Hospital of Eastern Ontario (CHEO), University of Ottawa, Ottawa, ON, Canada.

Background:

Recently, a microbial community to cancers of the pancreas and the biliary tract has been under the lens to identify a distinct microbiome composition associated with pancreatic cancer (PC) and extra-pancreatic biliary cancer (EPC).

Methods:

We investigated bile microbiota in patients with malignant pathologies of the biliary and pancreatic tract and evaluated if there is a different microbiological pattern in subjects with pancreatic and extra-pancreatic biliary tract cancers. One hundred forty-five positive bile cultures of Italian patients who underwent cholangiopancreatography (ERCP) with PC and EPC cancer hospitalized from January 2006 to December 2020 in a QA-certified academic surgical unit were investigated for aerobic, anaerobic, and fungal organisms.

Results:

In Table 1 we reported the characteristics of the 145 patients with pancreatic and extra-pancreatic cancer. Gram negative bacteria were isolated in 80% of bile cultures, both Gram positive and Gram-negative bacteria were detected in 10% of cancer patients. 12/145 (17.4%) patients showed candida spp in bile samples. In Table 2, we report the isolates individuated in this study. Particularly, some patients showed more isolates (Gram negative, Gram positive, or both). Specifically, Table 2 shows about Gram negative bacteria a significant less frequent of bacteria such as *M. morganii*, *P. agglomerans*, *E. meningoseptica*, *Serratia* spp, *Delftia acidovorans*, and *Brevundimonas* spp; while a significant most frequent were *Klebsiella* spp, *Escherichia coli*, and *Pseudomonas* spp. For Gram positive bacteria a significant less frequent were *Staphylococcus* spp and *Streptococcus* spp; while *Enterococcus* spp was the bacteria most frequent.

We observed that the PC group had a significant presence of patients of greater age than the EPC group ($p=0.0351$). Among Gram-negative bacteria, *Escherichia coli* and *Pseudomonas* spp were the most frequent in the EPC group. In PC group, *Escherichia coli*, *Klebsiella* spp and *Pseudomonas* spp were the most frequent. In addition, both groups had *Enterococcus* spp as the most frequent bacteria. In comparing EPC and PC groups, we observed a significant presence of Gram-negative ($p=0.0005$) and *Candida* spp in PC compared with EPC group ($p=0.0032$). In contrast, no significant differences for Gram-positive were found ($p=0.26$). In Table 3, in EPC group, among Gram negative we observed a significant less frequent of *Acinetobacter* spp; while *E. coli* and *Pseudomonas* spp were the Gram negative most frequent. In PC group the Gram negative significant less frequent were *M. morganii*, *P. agglomerans*, *E. meningoseptica*, *Serratia* spp, *Brevundimonas* spp, *Alcaligenes faecalis* and *Enterobacter* spp; while *E. coli*, *Klebsiella* spp and *Pseudomonas* spp were the Gram-negative bacteria most frequent. In addition, about Gram positive both groups had *Enterococcus* spp the most frequent bacteria. About the comparison between EPC and PC group, we observed a significant presence of Gram negative and *Candida* spp in PC in comparison with EPC group (53.10% vs. 23.66%, $p=0.0005$; 7.59% vs. 0.69%, $p=0.0032$, respectively), while no significant differences for Gram positive were found ($p=0.26$). In addition, from bivariate analysis between cancer groups and Gram negative a significant association was found ($p=0.0187$). In particular by post hoc z-test, it resulted that in EPC group *Alcaligenes faecalis* was the bacteria most frequent ($p=0.039$) and *M. morganii* was the bacteria less frequent ($p=0.014$), while in PC group, we found a significant less frequent bacteria such as *M. morganii* ($p=0.0196$), *P. agglomerans* ($p=0.0196$), *Serratia* spp ($p=0.0104$), *Alcaligenes faecalis* ($p=0.002$), and *Enterobacter* spp ($p=0.0159$).

Conclusions: In our pancreatic and extra-pancreatic biliary tract cancer patients, we found a more prevalent gut species of Enterobacteriaceae, well-known in gut dysbiosis. The geographical difference in gut microbiota composition may influence the biliary habitats in our cancer population. The prevalence of *Candida* spp in subjects with pancreatic cancer supports the hypothesis of a correlation between mycobiome, bile microbiota, and pancreatic cancer. Distinct microbiome signatures may be associated with cancer in the pancreatic and biliary habitats.

Keywords: Pancreatic cancer, extra-pancreatic biliary cancer, bile microbiota

Reference: Aykut B, Pushalkar S, Chen R, Li Q, Abengozar R, Kim JI, et al. The fungal mycobiome promotes pancreatic oncogenesis via activation of MBL. *Nature*. 2019;574(7777):264-7. DOI 10.1038/s41586-019-1608-2
Matsukawa H, Iida N, Kitamura K, Terashima T, Seishima J, Makino I, Kannon T, Hosomichi K, Yamashita T, Sakai Y, Honda M, Yamashita T, Mizukoshi E, Kaneko S. Dysbiotic gut microbiota in pancreatic cancer patients form correlation networks with the oral microbiota and prognostic factors. *Am J Cancer Res*. 2021 Jun 15;11(6):3163-3175. PMID: 34249452; PMCID: PMC8263681. Sergi C, Di Carlo P, Gulotta G, D'Arpa F. Biliary microbiota in pancreatic cancer. *HPB (Oxford)*. 2019;21(12):1790. DOI 10.1016/j.hpb.2019.06.001

Table 1. Characteristics of 145 patients with pancreatic and extra-pancreatic biliary cancer

Parameters	Sample
Patients	145
Age at microbiological analysis	
Mean±SD	75.1±10
Median (IQR)	76(69;82.25)
Gender	
Male	54.5% (79)
Female	45.5% (66)
Cancer	
Pancreatic	64.8% (94)
Extra-pancreatic	35.2% (51)
Bacteria (# patients)	
Gram-	82.8%(120)
Gram+	3.45%(5)
Both	11.03%(16)
Fungus (# patients)	
<i>Candida</i> spp	2.76%(4)
<i>Candida</i> spp and Gram-	2.76%(4)
<i>Candida</i> spp and Gram+	2.76%(4)
<i>Candida</i> spp and Gram- and Gram+	0.0%(0)

Table 2. Strains isolated from 145 patients with pancreatic and extra-pancreatic cancer

Isolates on 145 patients	%(Nr)
Gram- (patients)	82.76% (120)†
<i>M. morganii</i>	0.83%(1)***
<i>P. agglomerans</i>	0.83%(1)***
<i>E. meningoseptica</i>	1.67%(2)***
<i>Serratia</i> spp	1.67%(2)***
<i>D. acidovorans</i>	2.50%(3)***
<i>B. spp</i>	2.50%(3)***
<i>A. faecalis</i>	3.33%(4)
<i>Enterobacter</i> spp	4.17%(5)
<i>Achromobacter</i> spp	5.83%(7)
<i>Citrobacter</i> spp	5.83%(7)
<i>Acinetobacter</i> spp	6.67%(8)
<i>Stenotrophomonas</i> spp	8.33%(10)
<i>Klebsiella</i> spp	15.0%(18)**
<i>E. coli</i>	24.17%(29)**
<i>Pseudomonas</i> spp	31.67%(38)**
Gram+ (patients)	14.48%(21)†
<i>Staphylococcus</i> spp	4.76%(1)***
<i>Streptococcus</i> spp	9.52%(2)***
<i>Enterococcus</i> spp	90.48%(19)**
<i>Candida</i> spp	8.28%(12)

Table 3. Strains isolated from EPC and PC group

Isolates on 145 pz.	EPC Group %(N)	PC Group %(N)	EPC vs. PC p-value (Test)
Gram- (patients)	29.66% (43)	53.10% (77)	0.0005*(C)
<i>M. morganii</i>	2.33% (1)	0.0% (0)***	
<i>P. agglomerans</i>	2.33% (1)	0.0% (0)***	
<i>E. meningoseptica</i>	2.33% (1)	1.30% (1)***	
<i>Serratia</i> spp	4.65% (2)	0.0% (0)***	
<i>D. acidovorans</i>	2.33% (1)	2.60% (2)	0.0187* (C)
<i>Brevundimonas</i> spp	4.65% (2)	1.30% (1)***	<i>A. faecalis</i> (EPC)**, $p=0.039(Z)$
<i>A. faecalis</i>	9.30% (4)	0.0% (0)***	<i>Acinetobacter</i> spp (EPC)***, $p=0.0196(Z)$
<i>Enterobacter</i> spp	9.30% (4)	1.30% (1)***	<i>M. morganii</i> (PC)***, $p=0.0196(Z)$
<i>Acinetobacter</i> spp	0.0% (0)***	10.39% (8)	<i>P. agglomerans</i> (PC)***, $p=0.019$
<i>Achromobacter</i> spp	6.98% (3)	5.19% (4)	<i>Serratia</i> spp (PC)***, $p=0.0104(Z)$
<i>Citrobacter</i> spp	4.65% (2)	6.49% (5)	<i>A. faecalis</i> (PC)***, $p=0.002(Z)$
<i>Stenotrophomonas</i> spp	4.65% (2)	10.39% (8)	<i>Enterobacter</i> spp (PC)***, $p=0.01$
<i>Klebsiella</i> spp	11.63% (5)	16.88% (13)**	
<i>E. coli</i>	27.91% (12)**	22.08% (17)**	
<i>Pseudomonas</i> spp	25.58% (11)**	35.06% (27)**	
Gram+ (patients)	5.52% (8)	8.97% (13)	0.26 (C)
<i>Staphylococcus</i> spp	0.0%(0)	7.69% (1)	
<i>Streptococcus</i> spp	0.0%(0)	15.38% (2)	0.37(C)
<i>Enterococcus</i> spp	100%(8)**	84.62% (11)**	
Fungus (patients)	0.69%(1)	7.59% (11)	0.0032*(C)
<i>Candida</i> spp	100%(1)	100%(11)	

† = there are patients with more isolates;

* = significant test;

**=significant most frequent;

***=significant less frequent.

T= t-test;

MW=Mann Whitney test was used in the case of the distribution was not normal.

C = chi-square test;

F= Fisher's exact test;

Z= post hoc z-test;